News|Articles|November 10, 2025
Day 4 Recap: SDPA Fall 2025
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- Andrew Baker stressed leadership, inclusivity, and member engagement as crucial for dermatology's future growth and collaboration.
- Joseph Gatti emphasized the importance of mutual respect and collaboration between PAs and dermatologists to improve patient care.
Catch up on coverage from the fourth day of the 2025 SDPA Fall Conference held in San Antonio, Texas.
Advertisement
To stay informed with the latest conference insights, follow us on social media and
Derm Dispatch: SDPA President-Elect Andrew Baker, MBA, MPAS, PA-C, Shares His Vision
Andrew Baker, MBA, MPAS, PA-C, discusses leadership and inclusivity in dermatology at the SDPA Fall Conference, emphasizing collaboration and member engagement for future growth.
Joseph Gatti, DMSc, MPAS, MBA, PA-C, on Optimizing Collaboration and Mutual Respect Between PAs and Dermatologists
Joseph Gatti, DMSc, MPAS, MBA, highlights the importance of collaboration between PAs and dermatologists, emphasizing mutual respect and the role of PAs in enhancing patient care.
How AI Is Transforming Skin Cancer Diagnosis
Renata Block, DMSc, MMS, PA-C, explores how AI could enhance dermatology, improving skin cancer diagnosis while emphasizing the vital role of human clinicians in patient care.
From Lifestyle to Lymphoma: Heather Goff, MD, MPH, Shares Diverse Insights at SDPA Fall 2025
Heather Goff, MD, MPH, shares vital insights on lifestyle, ethics, and cutaneous lymphomas at SDPA Fall 2025, highlighting the future of dermatology.
Stay tuned to Dermatology Times all weekend for
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
